Pneumotox. vs NbN3

Pneumotox®: The drug-induced/iatrogenic respiratory disease website & App. The companion website and App Cardiotox® cover drug-induced cardiotoxicity. By Philippe Camus MD. Professor (emeritus) - Board-certified in pulmonary medicine and cardiology,- Université Bourgone-Europe, Dijon, France. Pneumotox is an aid to the diagnosis and management of respiratory diseases and reactions suspected of being induced by drugs, chemicals, and of iatrogenic origin. Causality assessment and exact diagnosis are the full responsibility of the user. Pneumotox is designed to provide regularly-updated information on drugs causing pulmonary toxicity (>1,700 agents), patterns of involvement (>820) and bibliography (>10,700 as of August 2026) within a few minutes. That may be the crux in emergency situations. Yet, double-checking in and from other sources is indicated. Pneumotox rests on a bibliographic repository built since 1978, which amounts to >50,000 references overall, the vast majority of which is indexed in PubMed. All references were and are carefully reviewed for reliability and causality by the founder, then indexed under the corresponding drug or agent in Pneumotox. Pneumotox can be assessed by causative drug(s), chemicals, herbals, substances of abuse, inhaled incl. e-cigarettes, vaping, inhalants, gases, ionizing radiations (providing the list of patterns), or by patterns of involvement (providing the list of causal drugs/agents). Drug names are generic (International Nonproprietary Names (INN), alphabetical), not brand ones. It may be appropriate to check the exact composition of any proprietary drug, as any other added substance or excipient can be pneumotoxic. Matching generic and brand names which differs with country is the responsibility of the user. Patterns are grouped by families according to the main anatomic site of involvement. If a drug or drug reaction is listed in Pneumotox, that does not equate the patient is demonstrating toxicity. A “Diagnosing DIRD” window in Pneumotox (top panel) may help secure the diagnosis. Lack of case or cases in the literature or in Pneumotox does not exclude a diagnosis of drug toxicity as there may be unpublished cases, you may be seeing the first case ever, or we may have overlooked some information. In such situations, please inform us; Pneumotox cannot be held responsible. Pneumotox can be contacted by mail 7/365 for complementary information, tailored literature, and/or data on rechallenge with the drug. In any patient, particularly the ones with acute respiratory failure, ARDS or acute bronchospasm, exposure to drugs, substances, and/or chemicals must be done exhaustively with the patient, and if needed with the family, health professionals, pharmacy and/or law enforcement personel. And prompt removal of the drug can be lifesaving. Caution: drug withdrawal can produce a flare of the underlying condition for which the drug was exactly given. Deliberate rechallenge can be hazardous as fatal relapse of the respiratiory reaction can supervene. Early sampling of body fluids for drug and/or metabolites is indicated as early as possible, particularly in the severely ill. Knowledge of toxidromes and antidotes capable of countering adverse effects of drugs or chemicals is essential (ex: PMID ). Where in doubt, consider double-checking PubMed, your affiliated Safety for Medicines Department/Agency and the Pharmacovigilance Department of drug companies. They may host more and/or undisclosed information. Patients should be reassured as such incidents are rare oveall. If needed, they are invited to consult with their treating physicians. Monitoring common causal agents (with red digits in stars) for impending toxicity is strongly advised. You may contact Pneumotox anytime through the contact window. ALL RIGHTS RESERVED The current version of Pneumotox website and App were developed by Akyos Communication Dijon France, under the guidance of Philippe Camus MD

It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients. This practice is confusing. • Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature. • The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”. • In this second edition 22 new medications were added so NbN includes now 130 medications. This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth. The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.   Therefore this nomenclature is based on: 1. The need to treat now. 2. Updated neuroscience insights. 3. The judgment of the members of the taskforce. Along these lines, we have come up with the following proposal: The Nomenclature: Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action. We also added 4 additional dimensions 4 Additional Dimensions: Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.) Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included  Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve" Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour.   As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.